The Leukemia & Lymphoma Society (LLS) does some pretty neat things. As the world's largest voluntary health organization dedicated to funding blood cancer research, education, and patient services, LLS's mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.
One of the programs they offer that’s pretty neat is The First Connection program. It provides newly diagnosed patients, caregivers and their families the opportunity to speak with someone who has "been through it" by talking with a trained Peer volunteer by phone.
Trained Peers can share their experience in a hopeful way and provide helpful information for anyone still in the treatment process.
Information about Society and community resources are also available.
Patient and volunteers are matched by age, diagnosis and gender when possible.
Any blood cancer patient or caregiver is eligible to receive a call.
There is no charge for this program. Find out more at http://www.leukemia-lymphoma.org/all_page?item_id=398848.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...